The Problem
Glioblastoma multiforme (GBM) is the most common malignant and aggressive brain tumor in adults whose median survival time is usually less than 2 years post-diagnosis. GBM accounts for 52% of all primary brain tumors. It is especially hard to treat as chemotherapy drugs have a difficult time crossing the blood brain barrier (BBB)(Ramachandran et al., 2017). This project aims to bridge the gap between theoretical nanoscience and clinical therapeutics for GBM by developing a novel drug delivery system (DDS) specifically for GBM. Most current DDSs developed have not been FDA approved due to their low efficacy and unpredictability. Specializing a DDS for GBM therapy would represent a significant step forward for the field of medicine and, more importantly, for patients suffering from this disease (Norouzi et al., 2018). The project will build upon work done by other scholars to develop implantable DDS for GBM using nanofiber technology, but will investigate the biocompatibility of certain nanofiber material hybrids with the GBM tumor microenvironment for a novel approach to this worldwide problem.
Research Questions |
|
Contact: [email protected]